Slide 1: AI-Powered, Portable Brain MRI
Exhibit 99.2 AI-POWERED, PORTABLE BRAIN MRI ® The Swoop Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck – October 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive A
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections
Slide 3: Q3 2026: Inflection in a Strengthening Business
Q3 2026: Inflection in a Strengthening Business Preliminary Revenue +53%, Preliminary Cash Burn -29% Sequentially 1 Q3 Preliminary Results Recent Milestones FY2026 Guidance Strong Outlook 2 Reaffirmed ~$6.0M Revenue FDA Clearance & Expected Revenue: De-risked, Disruptive AI- Up ~53% Sequentially Lau
Slide 4: Evolution of Brain Imaging
Evolution of Brain Imaging Democratization, Decentralization, and Automation for Better Brain Health THE GATEWAY Restricted, Hospital-Centric Universal, Patient/Consumer Centric Hospital Shielded facility Office • Concierge • Longevity • Mobile • + Community Brain Care Brain Care for disease managem
Slide 5: Hyperfine's Miniaturized MRI Technology Could Drive the Future of Imaging
Hyperfine’s Miniaturized MRI Technology Could Drive the Future of Imaging A suite of proprietary imaging technologies and know-how that enable Miniaturized MRI for a full range of applications with proven usability & scalability More Than a Portable Brain MRI Company... 5 PROPERTY OF HYPERFINE. ©202
Slide 6: The Swoop System Transforms and Expands the Reach of Brain Imaging
The Swoop System Transforms and Expands the Reach of Brain Imaging Diagnostic Image Quality Portable, Compact Design Goes Simplified Set Up and Scanning for Directly to the Patient Broad Usability Clinicians Can Act On USING THE SWOOP SYSTEM IMPROVES MRI CAPACITY AND ACCESS WITH MEANINGFUL CLINICAL
Slide 7: MRI is the Clinical Gold Standard, But Capacity and Access Are Limited
MRI is the Clinical Gold Standard, But Capacity and Access Are Limited The MRI You Know The MRI You Wish For Significantly less expensive, no High-cost and complex site shielding or siting required. requirements limit access Available at any healthcare facility Need for highly trained No dedicated p
Slide 8: Large Market Potential Bringing MRI to Multiple Sites of Care
Large Market Potential Bringing MRI to Multiple Sites of Care 1 Sizeable and Growing US TAM Through New Sites of Care $1.5B $6B+ $16B+ Outpatient Settings Community Settings Inpatient Settings 2025+ 2026+ 2023+ 2 Emergency departments Urgent care facilities Adult critical care 4,000+ 10,000+ Neurolo
Slide 9: Addressing Critical Unmet Needs in Neurological Disease
Addressing Critical Unmet Needs in Neurological Disease MRI access remains a critical gap — Swoop system brings point-of-care brain imaging to acute and chronic neurodegenerative conditions Sources: Published literature and company data on file. Stroke Dementia 12.2M 1.9M 1 in 4 55M+ 139M 2 in 3 new
Slide 10: Solid Fundamentals: Accelerating Growth
Solid Fundamentals: Accelerating Growth Development, Clinical & Early Compelling STRATEGY Commercial EXPANSION Commercial FOUNDATION • Model 2 Swoop System Launch • First Mover Advantage • Outstanding market feedback on Optive AI image quality Hospital Office International • ~200 Issued Patents • Pl
Slide 11: How Close Are We to Conventional MRI?
How Close Are We to Conventional MRI? 0.064T Swoop System 1.5 T † Powered by Optive AI Software* Conventional MRI 11 PROPERTY OF HYPERFINE ©2026. All rights reserved. * Sequence image acquired with Model 2 Swoop system hardware. † 1.5 T conventional MRI scans performed in 2018
Slide 12: Image Quality of Next-Gen Swoop System to Drive Broad Adoption
FLAIR (Swoop System) FLAIR (High-field 3T) Image Quality of Next-Gen Swoop System to Drive Broad Adoption Image Quality Approaching Conventional MRI Case Study of Swoop System vs. High-Field 3T 63-year-old female with history of prior infarct presenting with new-onset headache. Physicians performed
Slide 13: AI-Enabled Imaging Software
AI-Enabled Imaging Software Advanced, AI-driven image reconstruction to ultra-low field MRI—unlocking clearer images at lower field strengths Reduces noise and blur with deep learning, enhances image clarity and consistency, provides sharper anatomical detail to support confident diagnoses at the po
Slide 14: Robust Commercial Growth Strategy Driven By Diversified Business Verticals
Robust Commercial Growth Strategy Driven By 3 Diversified Business Verticals US NEUROLOGY OFFICE IAC NEURO PMR CONTRAST PMR Accreditation (Enrolled) INTERNATIONAL Initial UK/CE Initial India Model 2 Swoop Clearance Clearance UK/CE Clearance Critical Care Emergency Hospital IDNs US HOSPITAL (Adult &
Slide 15: Hospital Business
Hospital Business • Compelling clinical utility in critical care, emergency triage, neurosurgery and neuro follow up in adults & peds • Strong economic value proposition o Swoop system scans qualify for existing reimbursement (CPT 70551) o Opportunity to increase revenue, cost savings and optimized
Slide 16: Office Business
Office Business 1,2 • A typical neurologist orders 500–600 MRIs annually for neurologic conditions such as headaches, dementia, tumor, MS, surgery follow-up • 90% of private neurology practices don’t have on-site MR 3 imaging • Affordable and appealing, plug-and-play Swoop system o No specialized si
Slide 17: International Business
Model 1 Swoop system International Business • Compelling clinical utility transferable globally • Selling primarily into the hospital setting, demonstrated value proposition in remote settings • Optive AI software launched in 10 European languages in Q1’26 • CE Mark and UKCA Mark approvals for both
Slide 18: Scalable Commercialization with US Direct Sales and Global Distribution Network
Scalable Commercialization with US Direct Sales and Global Distribution Network INSTALLED BASE 1 Over 225 Swoop Systems Globally DIRECT DISTRIBUTORS Dedicated Selling & Implementation Teams (~15 FTE in Total) 10+ Markets (2 FTE in Total) Healthy US Pricing & Recurring Revenue Swoop System Manufactur
Slide 19: Innovation: Product and Clinical Evidence
Innovation: Product and Clinical Evidence AI-powered software releases, targeted labeling expansion and new use cases to broaden clinical utility Product Innovation Clinical Evidence & Expansion ▪ Model 2 Swoop system: powered by Optive AI ▪ NEURO PMR published: Portable MRI showed 92% software, lau
Slide 20: Execution Drives Growth and Financial Discipline
Execution Drives Growth and Financial Discipline Record Quarterly Preliminary Revenue, with Revenue > Cash Burn for the First Time Q2 2026 % Change Q3 2026 THREE MONTHS ENDED 1 Estimate Revenue $6.0M $3.9M 53% 2 Net Cash Burn $(5.6)M $(7.9)M 29% 2025 % Change NINE MONTHS ENDED 2026 1 Estimate (Septe
Slide 21: Multiple Catalysts Driving a Durable Revenue Trajectory
Multiple Catalysts Driving a Durable Revenue Trajectory Drivers & Catalysts Model 2 Swoop system powered by Optive AI software Ongoing $6.0 6 • US rollout of Model 2 Swoop system & latest 2 $5.3 Optive AI software 5 • Growing adoption in ED, hospital clinics, and critical care environments $3.9 $3.9
Slide 22: Solid Financial Fundamentals
1 Solid Financial Fundamentals Key Takeaways Strong Revenue Growth and Realizing Operating Leverage • Transitioned to Commercial Stage 2 REVENUE AND GROSS MARGIN CASH BURN Organization in 2025 • Model 2 Swoop System Launched FY26 Guidance 2025 2026 Est. Mid’25 in U.S. 25 GM%: 50-55% 40 • Office Mark
Slide 23: Platform Technology Expansion Opportunities
Platform Technology Expansion Opportunities Hyperfine CORE Technology is Well Positioned to Deliver in Multiple Markets with Additional 1 Growth and Value-added Services Future Next Now Mobile for acute care Mobile brain health Expanded sequence offering Neuro and private practice Expansion Contrast
Slide 24: Leadership Team With Proven Track Record of Success
Leadership Team With Proven Track Record of Success Maria Brett Hale Tom Rob Chief Administrative Fasciano, PhD Sainz Teisseyre, PhD Officer and Chief President and Chief Chief Operating Chief Regulatory Financial Officer Executive Officer Officer and Quality Officer Rafael Donnay Eric Chi Nguyen To
Slide 25: Hyperfine, Inc. Opportunity
Hyperfine, Inc. Opportunity Broad Indications Prolific Innovation Large TAM Strong Proprietary and Applicability Engine First-Mover Position • $16B+ US device market • Brain imaging of • Image quality • Portable MR category potential across patients of all ages approaching leader inpatient, outpatie
Slide 26: FAYPERFINE.
FAYPERFINE.